| 000 | 01901 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250516082113.0 | ||
| 264 | 0 | _c20120802 | |
| 008 | 201208s 0 0 eng d | ||
| 022 | _a1432-2277 | ||
| 024 | 7 |
_a10.1111/j.1432-2277.2012.01448.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLaMattina, John C | |
| 245 | 0 | 0 |
_aAlemtuzumab as compared to alternative contemporary induction regimens. _h[electronic resource] |
| 260 |
_bTransplant international : official journal of the European Society for Organ Transplantation _cMay 2012 |
||
| 300 |
_a518-26 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAlemtuzumab |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xtherapeutic use |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xadverse effects |
| 650 | 0 | 4 |
_aAntilymphocyte Serum _xtherapeutic use |
| 650 | 0 | 4 | _aBasiliximab |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGraft Rejection _xetiology |
| 650 | 0 | 4 | _aGraft Survival |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aInfections _xetiology |
| 650 | 0 | 4 | _aKaplan-Meier Estimate |
| 650 | 0 | 4 |
_aKidney Transplantation _xadverse effects |
| 650 | 0 | 4 |
_aLeukopenia _xetiology |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aRecombinant Fusion Proteins _xtherapeutic use |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aMezrich, Joshua D | |
| 700 | 1 | _aHofmann, R Michael | |
| 700 | 1 | _aFoley, David P | |
| 700 | 1 | _aD'Alessandro, Anthony M | |
| 700 | 1 | _aSollinger, Hans W | |
| 700 | 1 | _aPirsch, John D | |
| 773 | 0 |
_tTransplant international : official journal of the European Society for Organ Transplantation _gvol. 25 _gno. 5 _gp. 518-26 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1432-2277.2012.01448.x _zAvailable from publisher's website |
| 999 |
_c21600418 _d21600418 |
||